Healthcare Overview... Part 1?

By popular demand we’re doing a new overview, this time focusing on healthcare (Finally!). We’re going to keep this simple and stick with three basic buckets. 1) Healthcare Equipment, 2) Bio-Technology and 3) Pharmaceuticals. If there is a lot of demand for an additional space (or sub-segment within the sector) we’ll add it but this should serve as a solid overview given that these three sectors are in the news everyday (so it seems).

Notably, interest in the healthcare sector is likely being bid-up because of recent M&A activity (tax inversions) and stock price performance on the bio-medical side (breakthrough drugs). In short, a lot of people are interested in health care simply because it is *hot* right now. This is similar to the high level of interest in the internet sector.

With that said, here’s the high level overview.

--------------
Notes to be aware of before beginning:
1) If you are shooting for investment banking, having a background in healthcare is certainly not necessary. It may help with your spin (IE: a dual major in biology and finance would be better than solely finance) but certainly isn’t needed.

2) If you are shooting for healthcare from an investment perspective (think Equity Research, Healthcare specific investing funds) then advanced knowledge certainly helps. IE: many Equity Research analysts have PHDs in the healthcare space (naturally this applies to the buyside as well if they make the switch).

3) We are not covering hospital management, health care services (similar to biz services), health care insurance or Healthcare REITs. The reason why is these segments can be classified under different umbrellas. As an example healthcare REITs could simply be under real estate and Insurance could simply be under FIG (we already covered Insurance in detail). Finally, the last sector we *should* touch on is life sciences, but we’ll wait to see if people are interested in the space.

Valuation Backdrop: First and foremost, the healthcare sector derives much more of its value from the products and medical treatments created than any valuation metric used. In fact, this is exactly why valuation is the least important part of the process. The real value in healthcare stocks, and why they can be extremely volatile in spaces such as bio-technology come from the products. Products, products, products!

Now that we’ve gone over the importance of understanding the drugs and products, if you’re looking for specific metrics for valuation you should then turn to the following:

1) EV/EBITDA
2) Discounted Cash flow
3) Price to Earnings
4) Free Cash Flow Multiples
5) EV/Sales

The most common starts with the EBITDA metric as it is used across the Health Care space. The EV/EBITDA metric starts as the baseline and as you become more interested in the asset you’d build out a full discounted cash flow model and predict earnings power/upside to drug/product launches. Nothing fancy and as expected, higher growth companies would lean toward EV/Sales metrics.

With that lets go ahead and look at each sector.

Healthcare Equipment/Devices (SYK, JNJ, ISRG)

One of the larger segments within healthcare, equipment and devices can include: 1) joint replacements, 2) trauma surgeries; 3) surgical equipment and navigation systems; 4) endoscopic and communications systems; 5) neurosurgical, neurovascular and spinal device.

Instead of going through each one of these major segments we can simplify it as follows:

Reconstructive Surgery (joint replacements, trauma): While difficult to pin down, for the surgery market you’re going to look at the market in terms of overall replacements and market share within this space. As a simple example, you can expect a million or so hip/knee replacements per year (costs per surgery can exceed $10K).

We can do an entire post outlining different estimates for each type of surgery or procedure (~4+ million hernia repair procedures, ~2M appendix removals a year, partial removal/reconstruction of a colon at ~2.5M per year) however the point is to estimate the number of procedures by market and build from there. Each surgery company you work with will have a different market it is addressing. Total costs of each surgery also have wide bands that range from as low as a few thousand dollars to tens of thousands.

Medical Devices (Instruments, Endoscopy): This sub-segment focuses on products to help examine the human body (particularly inside organs as you are all well aware). Roughly speaking, the endoscopy equipment market is estimated to be $28.2 billion in size as of 2013 and is expected to grow at 5-7% CAGR.

This is a bit easier to understand at a high level as most are more familiar with these products. You can splice the $28.2B into smaller sub-segments as well: cameras, processors, displays/monitors and other accessories (brushes, fluid devices).

NeuroTechnology (neurosurgical devices and spine related issues): Finally, we reach the neurotechnology/spinal market. While the neurotechnology market is difficult to size, if you are looking for spinal implants it is a ~$5-6B market (low single digit growth). In addition, if you want to split the spinal arena into spinal devices as well, you find that the market is growing at ~4-6% annually (2013 market is roughly $10-12B).

You were asking about M&A? As noted at the top of the post, lots of M&A continues to occur in this space. There is a reason why… Tax inversions AND aggressive M&A targets.

Tax Inversions: These are specifically *hot* in the healthcare space and a quick Google search will get you up to speed on why companies are doing this, the simple answer is this… to save on US taxes. You purchase a company overseas and reincorporate to avoid paying US taxes.

Clear M&A Strategies: An overlooked reason beyond tax inversions for the recent M&A activity is the relatively low hurdle rate to take on more acquisitions. Companies are spending more and more on M&A to obtain market share and grow revenue: hurdle rates as low as ~12% IRR.

Valuation: Here we’re looking at more classic healthcare valuations. So you should be thinking in terms of EBITDA/Cash flow and various forms of return metrics (IRR and ROIC).

Some Final Takeaways: Given the backdrop to healthcare equipment companies, you should also be aware of the importance of organic vs. inorganic revenue. This is certainly key as rampant M&A (as seen in this space) must be met by additional scrutiny from investors/shareholders as growth within each segment (Spine/Surgery/others) should not be 100% due to acquisitions.

Bio-Technology (GILD, AMGN)

This is one of the hottest spaces within the Health Care industry.

This sector is best explained with an example, starting with a Bio-tech Giant ($160B+) Gilead. The Company develops and commercializes medicine which can include hepatitis vaccines, work on HIV/AIDs related products and cardiovascular/respiratory issues.

As you can imagine, the key question here is:
“Does the cure work?”

This answer will then drive your total addressable market and your ability to sell the product at scale. If the vaccine/medicine works, margins and profits are high since the cost of re-creating the concoction is usually quite low.

As promised, here’s a large example:

Sofosbuvir (Sovaldi) was created by Gilead to treat Hepatitis C. The product costs between ~$84K for 12 weeks of treatment to $168K for 24 weeks of treatment. Here’s the kicker… The cure works 90% of the time.

Needless to say this created a large opportunity for the firm as the Company generated revenue of ~$3.48B in Q2 of 2014 from Sovaldi sales due to the high $1,000/pill price tag.

Risk/Reward: While this is a large example where a single quarter in sales were larger than the entire previous year for the product line, the downside would be 1) changes in regulation, 2) competing drug products with higher cure rates, 3) similar products with less side effects.

In short the bio technology space is driven primarily by drug innovation. You’re going to follow updates from the FDA, the launch of the product in multiple geographies and monitor competitor drug releases as well.

While working in this space you would track drug trials for curing XYZ disease by comparing different response rates (example drug A has 50% effectiveness and passed X trials, drug B has 65% and passed Y trials etc.). Essentially, you create a landscape of the competitive drug market and flag each drug as it passes through Phase I, Phase II trials and so forth.

For more information on Sovaldi you can check out their website: http://www.sovaldi.com/

If you’re interested in learning more about newer drug releases then you can stick with another example and follow Zydelig (a leukemia related drug).
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406387.htm

Valuation: Given the backdrop, these companies have higher volatility and trade at large multiples where 5-7x sales, 10-15x EBITDA and 15-30x earnings are not uncommon. From that basis, Bio-tech is a space where you’ll lean more to sales and EBITDA multiples and less towards the DCF.

Drivers of the Space: These companies generally have less revenue (as expected they are valued based on future of their drugs). Therefore the main driver is going to be a promising drug being released (would be on radars for acquisitions – depending on how far down the road they are) and the

Final Note: To be clear with regards to the Biotech space, we are not recommending any security. The industry requires quite a bit of research and the above explanation was simply an example of how an important medical breakthrough can lead to billions of dollars in revenue (a previous event). Solvadi is not a common occurrence as it won the FDA’s breakthrough therapy designation and was approved by the FDA in December of 2013. The goal of a top tier biotechnology investor is to understand when and where the next medical breakthrough will come. If you’re a banker, you’re looking to appropriately size the opportunity of the next break through (easier said than done).

Pharmaceutical Companies (JNJ, PFE, BMY)

Similar to Bio-tech we are going to use an example to highlight the main pieces of this segment. The biggest name brand company that people are aware of is… Johnson and Johnson. From a high level here are the primary markets they serve.

Immunology: This is estimated to be a ~$10B industry growing at mid-single digits. As the name implies, this refers to diseases caused by disorders within the immune system: Immunodeficiency (where immune systems fails to give a proper response), autoimmunity (immune system attacks its own host body). We can split the Immunology market into several pieces but we’re going to keep it simple for this post. Example product would be Stelara – used to treat psoriasis a skin disease (do not Google image that – you’ve been warned)

Oncology: This is a $4-5B market depending on who you ask growing at a faster clip of roughly double digits. Oncology in short is the study of tumors/cancer. To keep with the format, a sample product here would be Zytiga (prostate cancer treatment).

Diabetes: Another self explanatory market for you guys, here we’re looking at a ~$40 billion market growing at 6-10% annually. A good example of a diabetes drug would be INVOKANA (canagliflozin) a type II diabetes treatment.

Neuro/Mood Products: This market directly treats patients with mood disorders such as ADHD and schizophrenia. This market is roughly $40-50B in size and a sample product in this space would be esketamine.

Likely missing a few here but the above should serve as a solid high level view.

Valuation: In this space you can primarily look at the four classic valuation metrics given at the beginning of this post 1) EV/EBITDA, 2) Discounted Cash flow, 3) Price to Earnings and 4) Free Cash Flow Multiples. To provide some additional help for your napkin or back of envelope: Sales multiples of ~3.5-4.5x on a forward year basis, PEG’s of ~2-3x, P/Es of 15-30x

Drivers of the Space: As expected, the main drivers are positive trial results, changes in regulation and release of generics.

Final Thoughts: Similar to biotech we are looking at variable outlooks based on performance of new cures and treatment results from innovative products. That said the multiples are generally a bit lower due to large pharma companies having lower growth profiles relative to a large number of hyper growth bio-tech companies.

---

Some quick bullets to help you in recruiting

- Generally, healthcare practices are located in NYC/New Jersey/San Francisco
- Healthcare has quite a bit of activity so you would likely get experience in M&A and Equity/Debt raises improving your capital markets knowledge
- Beyond products, tracking phases of drug trials, naturally regulations play a big part in this space as well

There you have it, short and sweet (if you call 2,000+ words short!) overview. If there is another space within healthcare that people need more information on we may do a part two. However, the three spaces above cover the main sectors that are driving interest in the space.

Finally, we’ll likely continue with these if people are interested in more sector overviews.

***Yes we did ping couchy to contribute to the comments section since he said he would but we weren't able to connect***

 

Thanks! Great overview, especially helpful on the valuation aspects!

Having said that, I beg to differ on estimates for oncology and immunology market size. Those 2 are the most lucrative therapeutic areas - being conservative I'd say onco is at least 50b (Zytiga sales are already ~2b and that's just one drug in prostate cancer) and Immunology probably above that. An arthritis drug Adalimumab (Humira) cashed in something like 11b last year on its own. Sure there is some overlap between the two (leukaemia drugs), but even taking that into account the numbers for both spaces are certainly above 10b.

 

Probably another big sub-sector catalyst is Diagnostics (Dx). Many Dx companies are partnering across all healthcare verticals to mapping out the genome, determine proper clinical strategy, devise episodic care delivery for long-term/rare disease management, etc...

Imagine an early start to treating a potential oncogene disorder that will arise in your 50s when you're only 20? Crazy, but Dx companies can deliver such an opportunity.

 

For anything below 10bn in market cap in biotech / spec pharma, sum of the parts DCF and probability-adjusted NPV (rNPV) are probably the most common valuation methods to anticipate the pipeline... multiples are generally useless in determining an investment except for market-adjusted comparables for M&A.

There are a lot of practices in Boston, less so in New Jersey.

 
Best Response

Already sort of mentioned it, but you are basically leaving out 1/3 or more of HC out. These include hospitals, outpatient centers, managed care, pharmacies, distributors, PBM, HCIT, HC REITs, contract manufacturers, contract researchers, and lot of other random stuff like temp staffing, ambulatory services, animal health, dialysis centers, etc. Basically the space is pretty big outside of just drugs and devices. And for those interested in PE, lot of the PE activities happen in the other bucket.

 

I have a bias for managed care as that is where I spent my time, but I wanted to say that I don't agree that calling managed care similar to business services, and not including it makes any sense. I would agree that someone from healthcare services can move into business services... but calling causality/general insurance or bus.services the same as managed care isn't accurate. While you don't need a PhD to understand managed care, there is a lot of knowledge to learn about capitated payments, medicare/medicaid, accountable care orgs... and the list goes on. I didn't make a habit of following every ER analyst, but I don't remember the analysts that covered business services or FIG also covering UNH, HUM, AET. Basically the same argument for why the likes of HCA are not included. I have never heard anyone describe them as a anything else other than a hospital, which should be included in a "healthcare" overview. I get it that you probably spent your time in med devices, etc., but dismissal is bizarre- I wouldn't call everything else basically bus. services or a fancy REIT.

**edit- cleaned up a few words

 

Agree with a lot of the comments here. There is a large other subset (hospitals, HC reits, other) not included hence the "part 1?". In addition life sciences wasn't fully covered and as a commenter mentioned is more on the larger cap size, vs "smid" cap

Tried to cover the hotter sectors first (opinion!).

Hope couchy can show up and do at least one of the other sectors in the comments!

 

Just a quick correction - GILD purchased Pharmasset in a $10.8 billion acquisition that had created Sovaldi. They didn't create Sovaldi themselves. When I was in a SMIF in college (2011-2012) my partner and I pitched GILD and our fund bought it two days before they announced their "cure" of Hepatitis C during their Feb 2012 earnings call. The split-adjusted price we bought it at was 24.53. It's sitting around 106.52 now. Half good due diligence, other half luck. It was very interesting researching a biotech company. I would highly recommend it to anyone that is curious. I learned a ton of new info about the medical field, drug trials, the role of advertising in pricing, legislation/patent issues, etc.

"Decide what to be and go be it." - The Avett Brothers
 

Thanks so much for the review.

How much M&A activity is there specifically in the middle market for healthcare? Spoke with an analyst at a MM bank who was staffed on an absurd number of deals, but they were almost all equity offerings.

 

Sint rerum non dignissimos fugiat non. Tenetur quia voluptatem quia illo aut dolore nemo. Rerum accusamus aut sed est sunt itaque.

 

Qui eum recusandae alias molestias consequatur. Vel ad similique fugiat adipisci rem. Illo exercitationem harum eveniet illo.

Eos et maxime doloremque sit laudantium voluptate. Asperiores est ullam sequi facilis debitis facilis. Illum aliquid recusandae maiores et assumenda. Sequi corrupti nemo dignissimos dolor odio tempore ea ut. Reprehenderit illo reprehenderit autem voluptatem commodi. Qui possimus vitae ut omnis a voluptatem.

Dolores consequatur consequatur porro doloribus quia. Quas voluptatem laboriosam consequatur at modi non repellendus. Quia nesciunt vel facere nihil illum.

Magni ex recusandae eum et iusto. Amet amet doloribus accusamus impedit. Ad amet impedit non nihil accusantium aut. Ratione harum labore nihil qui qui placeat ut.

Career Advancement Opportunities

March 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. (++) 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

March 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

March 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

March 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (85) $262
  • 3rd+ Year Analyst (13) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (65) $168
  • 1st Year Analyst (198) $159
  • Intern/Summer Analyst (143) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”